Gautam Kainth

Managing Partner at TCP Health Ventures I Technology, Medtech & Life Sciences Specialist I M.S. University of Oxford I Early Stage Investor I Strategic Leader I NED I Speaker I PE I VC

📍 United Kingdom🔄 Updated September 2026💼 7 investments📅 7 years investing🗓 Last invested Mar 2023
VC🌍 United Kingdom
7
Total investments
0
Early stage
1
Mid stage
0
Late stage
7y
Years active

Portfolio

7 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor & Board Member
Mar 2023
Board Member
Jan 2023
Our mission is to prevent surgical complications through our patented technology that delivers preconditioning therapy.
Board Member
Apr 2022
improving care for patients with heart failure
Investor
Feb 2022
Supira Medical, a clinical-stage Shifamed portfolio company, is focused on development of a next-generation pVAD for use in high-risk patients undergoing interventional procedures and experiencing cardiogenic shock. To learn more about Supira Medical, please visit www.supiramedical.com.
Board Member
Dec 2021
Focused on providing effective and easy-to-use clot removal to efficiently treat venous thromboembolisms (VTE)
Board Observer
Dec 2021
Mental Fitness: The capacity to engage with life’s emotional and cognitive challenges proactively, enthusiastically, and with strength. Not as signs of weakness but as opportunities for growth. We’re building the tools to help health systems move forward. We’re empowering individuals with better health to face life’s challenges. And we’re building mental healthcare that is more personal, preventative, and powerful.
Experience · 11 entries
All (11)
Investments (7)
Board (6)
2023
Investor & Board Member
Mar 2023
Board Member
Jan 2023
Our mission is to prevent surgical complications through our patented technology that delivers preconditioning therapy.
2022
Board Member
Apr 2022
improving care for patients with heart failure
Investor
Feb 2022
Supira Medical, a clinical-stage Shifamed portfolio company, is focused on development of a next-generation pVAD for use in high-risk patients undergoing interventional procedures and experiencing cardiogenic shock. To learn more about Supira Medical, please visit www.supiramedical.com.
2021
Board Member
Dec 2021
Focused on providing effective and easy-to-use clot removal to efficiently treat venous thromboembolisms (VTE)
Show all 11 entries ↓
Investment activity
2019–2023 · 7 investments
20191202122022220232
Recent (last 2 years)Earlier